Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G ROSENBLUM

Showing results (221-230 of 243) with videos related to

Pageof 25
Sort By:
Molecular Cancer Therapeutics|September 21, 2014
Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBCHong Zhou, Khalid A Mohamedali, Ana Maria Gonzalez-Angulo, et al.
Biochemical Pharmacology|June 13, 2012
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphomaMi-Ae Lyu, Lan V Pham, Bokyung Sung, et al.
Journal for Immunotherapy of Cancer|January 11, 2025
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growthKhalid A Mohamedali, Brian Aguirre, Cheng-Hsiang Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trialD J Macey, E J Grant, L Kasi, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanomaJ L Murray, E S Kleinerman, S F Jia, et al.
The Journal of Investigative Dermatology|November 30, 2012
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentHong Zhou, Suhendan Ekmekcioglu, John W Marks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2008
Imaging of VEGF receptor in a rat myocardial infarction model using PETMartin Rodriguez-Porcel, Weibo Cai, Olivier Gheysens, et al.
The Lancet. Infectious Diseases|March 10, 2022
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safeHannah G Rosenblum, Julianne Gee, Ruiling Liu, et al.
The American Journal of Case Reports|June 10, 2021
Surgical and Radiological Management of Complicated Uterine Leiomyoma Aided by 3D Models in a Patient with Fibrodysplasia Ossificans ProgressivaMichelle Ho, Beau Y Park, Norman G Rosenblum, et al.
Journal of Women'S Health (2002)|April 12, 2024
U.S. Women with Invasive Cervical Cancer: Characteristics and Potential Barriers to PreventionHannah G Rosenblum, Julia W Gargano, Angela A Cleveland, et al.
Pageof 25

Showing results (221-230 of 243) with videos related to

Sort By:
Pageof 25
Molecular Cancer Therapeutics|September 21, 2014
Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBCHong Zhou, Khalid A Mohamedali, Ana Maria Gonzalez-Angulo, et al.
Biochemical Pharmacology|June 13, 2012
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphomaMi-Ae Lyu, Lan V Pham, Bokyung Sung, et al.
Journal for Immunotherapy of Cancer|January 11, 2025
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growthKhalid A Mohamedali, Brian Aguirre, Cheng-Hsiang Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trialD J Macey, E J Grant, L Kasi, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanomaJ L Murray, E S Kleinerman, S F Jia, et al.
The Journal of Investigative Dermatology|November 30, 2012
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentHong Zhou, Suhendan Ekmekcioglu, John W Marks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2008
Imaging of VEGF receptor in a rat myocardial infarction model using PETMartin Rodriguez-Porcel, Weibo Cai, Olivier Gheysens, et al.
The Lancet. Infectious Diseases|March 10, 2022
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safeHannah G Rosenblum, Julianne Gee, Ruiling Liu, et al.
The American Journal of Case Reports|June 10, 2021
Surgical and Radiological Management of Complicated Uterine Leiomyoma Aided by 3D Models in a Patient with Fibrodysplasia Ossificans ProgressivaMichelle Ho, Beau Y Park, Norman G Rosenblum, et al.
Journal of Women'S Health (2002)|April 12, 2024
U.S. Women with Invasive Cervical Cancer: Characteristics and Potential Barriers to PreventionHannah G Rosenblum, Julia W Gargano, Angela A Cleveland, et al.
Pageof 25